Topics:

Avastin wins FDA OK for advanced kidney cancer treatment

Avastin wins FDA OK for advanced kidney cancer treatment

Avastin (bevacizumab) plus interferon-alfa has been approved for the treatment of metastatic renal cell carcinoma, according to Genentech. Approval was based on phase III data from the AVOREN study, which showed a 67% increase in progression-free survival (10.2 months) compared to those who received interferon-alfa alone (5.4 months; hazard ratio = 0.60).

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.